EA201991927A1 - Новый иммуностимулирующий макролид - Google Patents

Новый иммуностимулирующий макролид

Info

Publication number
EA201991927A1
EA201991927A1 EA201991927A EA201991927A EA201991927A1 EA 201991927 A1 EA201991927 A1 EA 201991927A1 EA 201991927 A EA201991927 A EA 201991927A EA 201991927 A EA201991927 A EA 201991927A EA 201991927 A1 EA201991927 A1 EA 201991927A1
Authority
EA
Eurasian Patent Office
Prior art keywords
macrolide
mulating
new immunity
immunity
new
Prior art date
Application number
EA201991927A
Other languages
English (en)
Other versions
EA037729B1 (ru
Inventor
Ола Винквист
Роберт Валлин
Эмма Линдх
Мэт Грегори
Стивен Мосс
Original Assignee
Имьюн Систем Регулеишн Холдинг Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имьюн Систем Регулеишн Холдинг Аб filed Critical Имьюн Систем Регулеишн Холдинг Аб
Publication of EA201991927A1 publication Critical patent/EA201991927A1/ru
Publication of EA037729B1 publication Critical patent/EA037729B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/08—Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение обеспечивает иммуностимулирующий макролид. Макролид пригоден при лечении вирусных заболеваний и рака.
EA201991927A 2017-02-22 2018-02-22 Новый иммуностимулирующий макролид EA037729B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17157393 2017-02-22
PCT/EP2018/054336 WO2018153954A1 (en) 2017-02-22 2018-02-22 Novel immune stimulating macrolide

Publications (2)

Publication Number Publication Date
EA201991927A1 true EA201991927A1 (ru) 2020-01-15
EA037729B1 EA037729B1 (ru) 2021-05-14

Family

ID=58158874

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991927A EA037729B1 (ru) 2017-02-22 2018-02-22 Новый иммуностимулирующий макролид

Country Status (9)

Country Link
US (1) US10919927B2 (ru)
EP (1) EP3585793B1 (ru)
JP (1) JP7049356B2 (ru)
KR (1) KR102567014B1 (ru)
CN (1) CN110709408B (ru)
AU (1) AU2018226337B2 (ru)
CA (1) CA3054166A1 (ru)
EA (1) EA037729B1 (ru)
WO (1) WO2018153954A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11059846B2 (en) * 2017-02-22 2021-07-13 ISR Immune System Regulation Holding AB (publ) Immune stimulating compound
AU2019237257A1 (en) * 2018-03-23 2020-10-15 ISR Immune System Regulation Holding AB (publ) Combinations of macrolide compounds and immune checkpoint inhibitors
WO2022049260A1 (en) * 2020-09-03 2022-03-10 ISR Immune System Regulation Holding AB (publ) Vaccine comprising an antigen and a tlr2 agonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1100504A (en) 1967-08-16 1968-01-24 Pliva Pharm & Chem Works Erythromycin oxime and 9-amino-3-o-cladinosyl-5-o-desosaminyl-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethylpentadecane-13-olide
SI7910768A8 (en) 1979-04-02 1996-06-30 Pliva Pharm & Chem Works Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS6176478A (ja) * 1984-09-21 1986-04-18 Meiji Seika Kaisha Ltd 新抗生物質ａｂ−８０物質およびその製造法
JP3631510B2 (ja) * 1994-05-26 2005-03-23 明治製菓株式会社 細菌バイオフィルム形成阻害剤
DE60140936D1 (de) 2000-04-13 2010-02-11 Biotica Tech Ltd Glycosylierte hybrid-verbindungen, deren herstellung und verwendung
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
GB0327721D0 (en) 2003-11-28 2003-12-31 Biotica Tech Ltd Polyketides and their synthesis
AU2006206952B2 (en) 2005-01-24 2011-08-18 Microbial Chemistry Research Foundation Anti-penicillin resistant pneumococci agent and novel 16-membered ring macrolide derivative
ATE468119T1 (de) * 2006-06-12 2010-06-15 Univ Ramot Verfahren zur behandlung von krebs

Also Published As

Publication number Publication date
JP2020516584A (ja) 2020-06-11
CN110709408B (zh) 2022-10-25
AU2018226337A1 (en) 2019-10-10
KR20190120264A (ko) 2019-10-23
KR102567014B1 (ko) 2023-08-14
JP7049356B2 (ja) 2022-04-06
US20190367551A1 (en) 2019-12-05
EA037729B1 (ru) 2021-05-14
WO2018153954A1 (en) 2018-08-30
US10919927B2 (en) 2021-02-16
AU2018226337B2 (en) 2021-07-22
EP3585793A1 (en) 2020-01-01
CA3054166A1 (en) 2018-08-30
EP3585793B1 (en) 2021-01-06
CN110709408A (zh) 2020-01-17

Similar Documents

Publication Publication Date Title
MX2019012233A (es) Anticuerpos anti-sirpa.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA202091134A1 (ru) Экзосомы для иммуноонкологической и противовоспалительной терапии
CL2021000704A1 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. (divisional de solicitud 668-2019)
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2020000774A2 (es) Rellenos de tejidos basados en ácido hialurónico de seda y métodos de utilizar los mismos
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
MX2022007522A (es) Anticuerpos anti-cd27.
EA201892294A1 (ru) Антитела и композиции против tim-3
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
EA201800148A1 (ru) Оспенная вакцина для лечения рака
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MY192385A (en) Methods of treating acute kidney injury
EA201991927A1 (ru) Новый иммуностимулирующий макролид
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
WO2018237010A3 (en) VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE